Pneumocystis jirovecii pneumonia future or investigational therapies: Difference between revisions
No edit summary |
m (Changes made per Mahshid's request) |
||
| Line 18: | Line 18: | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Pulmonology]] | [[Category:Pulmonology]] | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
Latest revision as of 18:44, 18 September 2017
|
Pneumocystis jirovecii pneumonia Microchapters |
|
Differentiating Pneumocystis jirovecii pneumonia from other Diseases |
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Pneumocystis jirovecii pneumonia future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Pneumocystis jirovecii pneumonia future or investigational therapies |
|
FDA on Pneumocystis jirovecii pneumonia future or investigational therapies |
|
CDC on Pneumocystis jirovecii pneumonia future or investigational therapies |
|
Pneumocystis jirovecii pneumonia future or investigational therapies in the news |
|
Blogs on Pneumocystis jirovecii pneumonia future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Future or Investigational Therapies
Pneumocystis Genome Project
Pneumocystis species cannot be grown in culture. Therefore, there is a limitation to the availability of the human disease causing agent, P. jirovecii. Hence, investigation of the whole genome of a Pneumocystis is largely based upon true P. carinii available from experimental rats which can be maintained with infections. The project is described in the site linked here. Genetic material of other species, such as P. jirovecii can be compared to the genome of P. carinii. Pneumocystis Genome Project